Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations
- 824 Downloads
BRCA1/2 mutations represent approximately 5 % of unselected Chinese women with breast cancer. However, the breast cancer risk of Chinese women with BRCA1/2 mutations is unknown. Therefore, the aim of this study was to estimate the age-specific cumulative risk of breast cancer in Chinese women who carry a BRCA1 or BRCA2 mutation. Our study included 1816 unselected Chinese women with breast cancer and 5549 female first-degree relatives of these probands. All probands were screened for BRCA1/2 mutation. The age-specific cumulative risks of BRCA1/2 carriers were estimated using the kin-cohort study by comparing the history of breast cancer in first-degree female relatives of BRCA1/2 carriers and non-carriers. Among the 1816 probands, 125 BRCA1/2 pathogenic mutations were identified (70 in the BRCA1 gene and 55 in the BRCA2 gene). The incidence of breast cancer in the first-degree female relatives of BRCA1/2 mutation carriers was significantly higher (3.7-fold and 4.4-fold for BRCA1 and BRCA2 mutation carriers, respectively) than in non-carriers. The estimated cumulative risks of breast cancer by age 70 years were 37.9 % [95 % confidence interval (CI) 24.1–54.4 %] for BRCA1 mutation carriers and 36.5 % (95 % CI 26.7–51.8 %) for BRCA2 mutation carriers, respectively. Our study suggests that the breast cancer risk of Chinese women with BRCA1/2 mutations appears to be relatively high by the age of 70. Therefore, genetic counseling, enhanced surveillance, and individual preventive strategies should be provided for Chinese women who carry a BRCA1/2 mutation.
KeywordsBRCA1 BRCA2 Breast cancer risk Chinese women
This study was supported by the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (no. 2014BAI09B08), the 973 project 2013CB911004, and Grants from the National Natural Science Foundation of China (nos. 81302330 and 81372832). The authors thank Dr. Hui Zhang (Beijing Institute of Genomics, CAS) for her help on data analysis.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
- 4.Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130. doi: 10.1086/375033 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Hopper JL, Southey MC, Dite GS et al (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study. Cancer Epidemiol Biomarkers Prev 8(9):741–747PubMedGoogle Scholar
- 17.Antoniou AC, Pharoah PD, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42(7):602–603. doi: 10.1136/jmg.2004.024133 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Evans DG, Shenton A, Woodward E et al (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8:155. doi: 10.1186/1471-2407-8-155 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Antoniou AC, Gayther SA, Stratton JF et al (2000) Risk models for familial ovarian and breast cancer. Genet Epidemiol 18(2):173–190. doi: 10.1002/(SICI)1098-2272(200002)18:2<173:AID-GEPI6>3.0.CO;2-R CrossRefPubMedGoogle Scholar
- 39.Beijing Municipal People’s Government (2013) Beijing municipal health and population health report. People’s Medical Publishing House, BeijingGoogle Scholar
- 45.Nelson HD, Pappas M, Zakher B et al (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. preventive services task force recommendation. Ann Intern Med 160(4):255–266. doi: 10.7326/M13-1684 CrossRefPubMedGoogle Scholar